Zanzalintinib fumarate is under clinical development by Exelixis and currently in Phase II for Oropharyngeal Cancer. According to GlobalData, Phase II drugs for Oropharyngeal Cancer have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zanzalintinib fumarate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zanzalintinib fumarate overview

Zanzalintinib fumarate (XL-092) is under development for the treatment of solid tumors such as metastatic renal cell carcinoma, metastatic urothelial carcinoma including the renal pelvis, ureter, urinary bladder, urethra cancer, metastatic castration resistant prostate cancer, metastatic hepatocellular carcinoma, papillary renal cell carcinoma, recurrent head and neck cancer squamous cell carcinoma, oral cavity cancer, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer and human epidermal growth factor receptor 2 negative breast cancer (HER2- breast cancer). The drug candidate is administered through oral route. It acts by targeting protein tyrosine kinases which constitutes of MET, VEGFR, AXL and MER, TYRO3.

It was under development for the treatment of non-small cell lung cancer.

Exelixis overview

Exelixis is a biopharmaceutical company that focuses on the development and commercialization of small molecule therapies for the treatment of cancer. The company’s marketed products include, Cometriq (cabozantinib), an inhibitor of multiple receptor tyrosine kinases; Cabometyx (cabozantinib) developed for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). The company’s pipeline product candidates include zanzalintinib, XB002 and XL102 for the treatment of advanced or metastatic solid tumors and CBX-12 for advanced metastatic refractory solid tumors. The company has collaborative partnerships with biopharmaceutical companies to advance the development of potential therapies for cancer and other serious diseases. Exelixis is headquartered in Alameda, California, the US.

For a complete picture of Zanzalintinib fumarate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.